Mitotic arrest deficient 2 (MAD2) is thought to be a key component of the mitotic checkpoint, which ensures accurate chromosome segregation. Reduced expression of MAD2 protein is associated with mitotic checkpoint abrogation and chromosomal instability in certain types of human cancers. To explore the possibility of developing a novel strategy for the treatment of cancer based on selective killing of mitotic checkpoint-defective or -competent cells, here we have investigated the effect of MAD2 expression on cellular sensitivity to checkpointtargeting anticancer drugs. We reintroduced MAD2 protein in a mitotic checkpoint-defective nasopharyngeal carcinoma cell line, CNE2, using an inducible expression vector. We found that overexpression of MAD2 led to an increased sensitivity to vincristine, which was accompanied by increased mitotic index and G2/M cell cycle arrest. In addition, increased phosphorylation of Raf, MEK1/2 and Bcl-2 was observed in MAD2-overexpressing cells in response to vincristine. Furthermore, inhibition of phosphorylation of MEK1/2 by its inhibitor PD098059 led to reduced sensitivity to vincristine, which was associated with decreased Bcl-2 phosphorylation. Our data suggest a role for MAD2 in the sensitization of cancer cells to certain mitotic checkpoint-targeting anticancer drugs.
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The proper segregation of chromosomes in anaphase is essential for the integrity of the genome. The mitotic checkpoint, also known as a spindle assembly checkpoint, ensures that cell division does not occur until all duplicated chromosomes align and attach to the spindle. One of the key components of the mitotic checkpoint is mitotic arrest deficient 2 (MAD2). MAD2 is found on the kinetochores, which link to both chromosomes and microtubules, and is thought to be crucial for generating the 'wait' signal to prevent the onset of anaphase in the presence of microtubule disruption (Li and Benezra, 1996; Amon, 1999; Wassmann and Benezra, 2001 ). Inactivation of MAD2 either by microinjection of anti-MAD2 antibodies or knockout of the MAD2 gene led to defective mitotic checkpoint and chromosomal instability (Kallio et al., 1998; Dobles et al., 2000) , indicating the essentiality of MAD2 for mitotic checkpoint control. Recently, we and others have reported that decreased expression of MAD2 protein is associated with a defective mitotic checkpoint in human cancers (Kallio et al., 1998; Wang et al., 2000 Wang et al., , 2002 and that exogenous MAD2 expression leads to the restoration of checkpoint (Wang et al., 2002) . However, the possible association between MAD2 expression and cellular sensitivity to microtubule-targeting agents such as vincristine and taxol, which remain front-line chemotherapeutic agents in cancer treatment, has not been studied. Since mitotic checkpoint defect is common in human cancers (Cahill et al., 1998; Lengauer et al., 1998; Takahashi et al., 1999; Kasai et al., 2002) and the cytotoxicity of most microtubule-inhibiting agents used in the treatment of human cancer acts through induction of mitotic arrest and apoptosis (Sherwood et al., 1994; Jordan et al., 1996) , we hypothesized that there might be a difference in drug sensitivity between the mitotic checkpointdefective and -competent human cancer cells. In addition, as MAD2 expression is crucial for mitotic checkpoint control as previously reported (Kallio et al., 1998; Dobles et al., 2000; Wang et al., 2000 Wang et al., , 2002 , it is possible that MAD2 may play a role in cellular sensitivity to microtubule-disrupting agents. Therefore, the expression of MAD2 may prove to be useful in selecting an efficient treatment for human cancer.
We have previously demonstrated that the nasopharyngeal carcinoma (NPC) cell line CNE2 shows relatively low levels of MAD2 expression and a defective mitotic checkpoint compared to other NPC cell lines and the mitotic competent HeLa cells (Wang et al., 2000) . In this study, we introduced exogenous MAD2 in CNE2 cells by cotransfecting a MAD2 expression plasmid driven by an ecdysone-inducible promoter (pIND(SPl)-MAD2) and the plasmid expressing the heterodimeric ecdysone receptor (pVgRXR) (Wang et al., 2002) . Three stable transfectant clones were isolated (CNE2-MAD2-C1 to C3) by selecting in culture medium containing both Zeocin (100 mg/ml) and G418 (800 mg/ml). Exogenous MAD2 expression was induced by exposure to 5 mm ponasterone A. As shown in Figure 1a , ponasterone A treatment (+P) resulted in a two to eight-fold increase in MAD2 levels in CNE2 cells compared to the untreated controls (ÀP). There was no significant change in population doubling (PD) The parental cell line CNE2 and three stable transfectant clones were then tested for their sensitivity to two microtubule-inhibiting anticancer agents, vincristine ( Figure 1b ) and taxol (Figure 1c ), using colonyforming assay in the presence (+P) or absence (ÀP) of ponasterone A. Both vincristine and taxol inhibit cell proliferation by interfering with microtubule dynamics. However, it is noteworthy that they have opposite effects on microtubule polymerization. Whereas vincristine binds to tubulin thereby inhibiting the formation of microtubules, taxol binds to polymeric microtubules and prevents their disassembly. Thus, vincristine and taxol represent two contrasting examples of microtubule inhibitors. We noted that the colony-forming ability of CNE2 and all three MAD2-transfected clones decreased progressively upon treatment with increasing doses of vincristine, if compared to the untreated controls, either in the presence or absence of ponasterone A (Figure 1b) . Thus, these cells are sensitive to vincristine regardless of the MAD2 status. In addition, there was no difference in cellular sensitivity to vincristine or taxol in the parental CNE2 cells cultured in the presence or absence of ponasterone A, indicating that ponasterone A treatment alone did not have any effect on cellular sensitivity to both drugs (Figure 1b and c) . However, in the CNE2-MAD2 cells, with the addition of ponasterone A (solidcolumns), a significant reduction of colony-forming ability was observed in the cells treated with vincristine than in the cells cultured without ponasterone A (open columns) (Po0.05) (Figure 1b) . These results indicate that the exogenously introduced MAD2 conferred an increased sensitivity to vincristine in CNE2 cells. In contrast, after treatment with taxol (Figure 1c) , there was only a slight decrease in colony-forming ability in the cells cultured in ponasterone A (+P), and the differential sensitivity was not statistically significant compared to the cells cultured in the absence of ponasterone A (ÀP, P>0.05).
To further confirm these findings, we studied three additional NPC cell lines that have been shown to have relatively high (CNE1 and 915) or low (CNE3) levels of MAD2 protein (Wang et al., 2000) . As shown in Figure 1d , we found that CNE1 and 915 cells were much more sensitive to vincristine with IC 50 (Inhibition concentration of 50% colony-forming ability) values of 1.3170.40 and 0.7570.34 ng/ml, respectively, compared to the CNE3 cells (IC 50 ¼ 2.6370.76 ng/ml) (Po0.05).
However, there was no significant difference in IC 50 values to taxol among the three cell lines (IC 50 CNE1 ¼ 0.3770.03 ng/ml; IC 50 915 ¼ 0.2870.07 ng/ml; IC 50 CNE3 ¼ 0.3470.03 ng/ml) (P>0.05). These results further support the findings on CNE2 cells that increased MAD2 is associated with cellular sensitivity to vincristine but not taxol in NPC cells.
It is generally accepted that microtubule-inhibiting agents such as nocodazole and vincristine can induce apoptosis following a cell cycle arrest at the G2/M phase (Sherwood et al., 1994; Jordan et al., 1996; Minn et al., 1996; Wahl et al., 1996) . To investigate whether MAD2-induced sensitization to vincristine is mechanistically linked to the induction of G2/M arrest and apoptosis, we evaluated the apoptosis rate and the mitotic index of vincristine-treated cells in the presence and absence of ponasterone A. When we stained the vincristine-treated cells with 4 0 6-diamidino-2-phenylindole (DAPI), there were no significant alterations in either apoptosis rate or mitotic index in the control CNE2 cells cultured in the presence or absence of ponasterone A (Figure 2 ), indicating that ponasterone A treatment alone did not affect vincristine-induced apoptosis and mitotic index. However, in the transfectants, the percentage of apoptotic cells was shown to be much higher in the cells cultured in ponasterone A (solid columns) than in the cells cultured without ponasterone A (open columns) ( Figure 2a ). In addition, the percentage of apoptotic cells was associated with an increased percentage of cells arrested at mitosis (Figure 2b) . Moreover, the expression of MAD2 correlated with the hypersensitivity to vincristine reflected by the decreased colony-forming ability (Figure 1b) , and with the induction of apoptosis and mitotic arrest ( Figure 2 ). For instance, the CNE2-MAD2-C3 cells showing the highest MAD2 levels displayed the highest sensitivity to vincristine. However, in the cells treated with taxol, there was no significant difference in the percentage of either apoptotic or mitotic cells between the cells cultured in the presence and absence of ponasterone A (data not shown). One argument would be that these cells failed to accumulate in mitosis simply because the taxol concentrations used in this study were too low. However, as shown in Figure 1 , the cytotoxicity of taxol (10-90% colonyforming inhibition) was similar to or higher than that of vincristine (5-50% colony-forming inhibition). Therefore, the failure to observe mitotic arrest in taxol-treated cells was unlikely due to the inadequate concentration of taxol in this study.
To investigate the mechanisms involved in the MAD2-induced hypersensitivity to vincristine, we assessed cell cycle profiles of vincristine-treated CNE2 cells by the use of flow cytometry. As shown in Figure 3 , in the cells expressing exogenous MAD2 (+P), a clear G2/ M arrest was observed in the CNE2-MAD2-C3 cells beginning at 24-h postexposure time. A decreased percentage of G2/M cells was found at 72 h after exposure to vincristine (3 ng/ml), which was accompanied by an increase in the percentage of sub-Gl phase cells. In contrast, in the cells expressing low levels of MAD2 (ÀP), there was no evidence of G2/M arrest and Figure 1 Effect of MAD2 expression on cellular sensitivity to vincristine and taxol. A 1.5 kb fragment containing the full-length human MAD2 cDNA was cloned into the EcoRI and Xbal sites of an expression vector pIND(SP1) driven by the ecdysone-inducible promoter (Invitrogen, CA, USA) (Wang et al., 2002) . The resulting construct pIND(SPl)-MAD2 (conferring neomycin resistance) was then cotransfected with pVgRXR vector (conferring Zeocin resistance), which permits the formation of a functional heterodimeric ecdysone receptor in mammalian cells. Using the calcium phosphate method, the stable pIND(SPl)-MAD2 and pVgRXR transfectants were generated by selecting in both neomycin (800 mg/ml) and Zeocin (100 mg/ml). To induce MAD2 expression in the transfectants, 5 mm of ponasterone A (Invitrogen, CA, USA) was added. In total, 700 cells were plated in six-well plates, resulting in approximately 100 colonies per well after 2 weeks culture in the presence (+P) or absence (ÀP) of ponasterone A (5 mm). Vincristine or taxol was added 24 h after plating the cells, and colonies that consisted of more than 50 cells were scored and compared to the solvent-treated controls after 12 days. Two wells were used for each concentration and each experiment was repeated at least three times. Results represent the means and standard error of the means the percentage of sub-G1 cells was much lower. Similar results were also found in CNE2-MAD2-Cl and C2 cells (data not shown). These results indicate that expression of exogenous MAD2 protein induced G2/ M arrest in response to vincristine treatment. One interpretation is that MAD2 plays a role in vincristineinduced mitotic arrest, which may have triggered apoptosis. This hypothesis was also supported by the flow cytometric data that a G2/M peak was clearly seen in the MAD2-overexpressing cells at an earlier time point of 24-48 h but was less evident at later time points (72-96 h), which was accompanied by the increased sub-G1 cells (Figure 3 ). In addition, the percentage of sub-G1 cells was increased with extended exposure time (from 5.6% at 24 h to 43.4% at 96 h). These results agree generally with the DAPI staining data that the percentage of apoptotic cells was increased with prolonged exposure to vincristine (Figure 2a) . It is understood that cells may undergo apoptosis subsequent to the mitotic block (Minn et al., 1996) .
In this study, there was no evidence of mitotic arrest in response to microtubule-disruption upon treatment with vincristine in the mitotic checkpoint-defective CNE2 cells expressing insufficient amounts of MAD2 (Figures 2 and 3, ÀP) . In contrast, an increased percentage of G2/M cells was observed in the MAD2-overexpressing cells (Figures 2 and 3, +P) . These results further support the notion that MAD2 acts as a molecular switch for mitotic checkpoint control in human cancers (Pennisi, 1998) . Previously, it has been reported that human lung cancer cells (A549) with a disrupted MAD2-dependent checkpoint have an increased sensitivity to microtubule-disrupting agents such as taxol and nocodazole (Zhang and Lees, 2001) and that low levels of MAD2 expression correlated with an increased sensitivity to microtubule-disrupting agents (Li and Benezra, 1996) . However, the apoptotic studies in these reports were performed at a relatively short exposure time (18 h) (Zhang and Lees, 2001 ). In the present study, we did not observe a difference in apoptosis rate between the cells expressing low and high levels of MAD2 until 48 h after drug treatment (Figure 2a) . Our apoptosis studies were also confirmed by colony-forming assay, which measures a cell's ability to divide for at least five times after drug treatment. It is to be determined whether cell-type-specific effects may explain the differential responses to microtubule-disruption. In this regard, our findings are generally consistent with a recent report on human adult T-cell leukemia in which a loss of mitotic checkpoint conferred cellular resistance to microtubule-disrupting agents such as vincristine (Kasai et al., 2002) .
A role for the activation of Raf, MAPK and p38 kinases in the mitotic checkpoint has been well described (Minshull et al., 1994; Takenaka et al., 1997 Takenaka et al., , 1998 Wang et al., 1997) . Induction of Raf/MAPK activation by microtubule-inhibiting agents has also been reported (Hayne et al., 2000) . With this in mind, we questioned if the Raf/MAPK pathway played a role in MAD2-induced sensitization to vincristine. The activation of Raf and MEKl/2 in CNE2 and CNE2-MAD2-C3 cells was examined by Western blot analysis using antibodies against phosphorylated Raf (Ser259) and MEKl/2 (Ser217/221). As shown in Figure 4b (+P), hyperphosphorylated Raf and MEKl/2 were found at 2 h after exposure to vincristine in the presence of ponasterone A, which corresponds to increased expression of MAD2 (Figure 4a , +P) in CNE2-MAD2-C3 cells but not in the control CNE2. However, the levels of unphosphorylated Raf and MEK1/2 remained unchanged (Figure 4b ). In contrast, there was no evidence of Raf or MEKl/2 hyperphosphorylation in the absence of ponasterone A (ÀP), which corresponds to the insufficient expression of MAD2 (Figure 4a, ÀP) . These results suggest that the exogenous expression of MAD2 correlates with the activation of Raf/MEK. However, we also noted that while early induction of MAD2 (C3, +P, 1-4 h) was associated with increased phospho-Raf (C3, +P, 2-4 h), there was no correlation between MAD2 accumulation and Raf phosphorylation at later time points (Figure 4a and b, C3, +P, 6-8 h). In contrast, phosphorylation of MEKl/2 was sustained even after the reduction of Raf phosphorylation (Figure 4b, C3, +P) , compared to cells cultured in the absence of ponasterone A. At the moment, we do not fully understand why and how Raf phosphorylation is downregulated in these cells. One possibility is that Raf phosphorylation might trigger the MAD2-independent negative feedback mechanism to prevent uncontrolled activation of the pathway. Probably the ubiquitously expressed cellular inhibitors of Raf kinase such as Raf kinase inhibitor protein (RKIP) may play a role in this regulation (Yeung et al., 1999) .
Since Raf phosphorylation is suggested to be responsible for inducing phosphorylation and thus inactivation of Bcl-2 and Bcl-xl, which leads to apoptosis in certain cell types (Blagosklonny et al., 1997; Huang et al., 1999; Fan et al., 2000; Stadheim et al., 2001) , we next studied the expression of Bcl-2 and Bcl-xl in CNE2-MAD2-C3 cells. We found that in the presence of ponasterone A (+P), there was an increase in the phosphorylated Bcl-2 protein (Figure 4 , C3, upper band), beginning at 4 h after exposure to vincristine, and its levels were further increased at later time points. In contrast, in the cells cultured in the absence of ponasterone (ÀP), the appearance of phosphorylated Bcl-2 was delayed (beginning at 6 h postexposure) and the relative amounts were much lower than in the cells expressing high levels of MAD2 (+P). However, there was no evidence of phosphorylated Bcl-xl either in the presence or absence of ponasterone A, indicating that Bcl-xl may not be involved in the vincristine-induced apoptosis in these cells. Currently, we do not understand which kinase is responsible for the phosphorylation of Bcl-2 in CNE2-MAD2-C3 cells treated with vincristine. We noted that ASK1/JNK1 has been suggested to be important in taxol-induced Bcl-2 phosphorylation and its inactivation in certain cell types (Yamamoto et al., 1999) . We are in the process of characterizing whether the ASK1/JNK1 pathway is involved in the Bcl-2 phosphorylation in NPC cells.
We did not observe the degradation of Bcl-2 protein after treatment with vincristine ( Figure 4c ). Apparently, Bcl-2 is phosphorylated and dephosphorylated on different sites by a variety of kinases and phosphatases (Srivastava et al., 1998; Dimmeler et al., 1999) . It remains controversial as to whether phosphorylation of Bcl-2 leads to proteosome-dependent degradation (Haldar et al., 1995; Brichese et al., 2002; Huang and Cidlowski, 2002) . Thus, further investigations are required to elucidate which sides of Bcl-2 are phosphorylated and exactly how Bcl-2 phosphorylation contributes to vincristine-induced apoptosis in CNE2-MAD2 cells.
Since it was reported that taxol induced Raf/Bcl-2 phosphorylation and apoptosis in certain cell types (Blagosklonny et al., 1997; Yamamoto et al., 1999), we Figure 3 Effect of MAD2 expression on vincristine-induced cell cycle perturbation in CNE2-MAD2-C3 cells. Cell cycle distribution was analyzed using a published protocol (Wang et al, 1998 . Briefly, the cells (5 Â 10 5 ) were fixed in 70% ethanol and stained with propidium iodide (50 mg/ml) and RNAse (1 mg/ml) for 30 min at 371C. They were then analyzed on an EPICS profile analyzer (Coulter, Miami, FL, USA). Results represent three independent experiments Figure 4 Effect of MAD2 expression on vincristine-induced Raf, MEKl/2, Bcl-2 and Bcl-xl phosphorylation in CNE2-MAD2-C3 cells. Approximately 30 mg protein was separated on a 15% SDS-polyacrylamide gel, transferred to nitrocellulose and incubated with antibodies against MAD2 (monoclonal, 1 : 500; Jin et al., 1998), phospho-Raf (Ser259) (polyclonal, 1 : 500; Cell Signaling Technology, USA), Raf (polyclonal, 1 : 200; Santa Cruz, USA), phospho-MEKl/2 (Ser217/221) (polyclonal, 1 : 500; Cell Signaling Technology, USA), MEKl/2 (polyclonal, 1 : 500; Cell Signaling Technology, USA), Bcl-2 (polyclonal, 1 : 300; Santa Cruz, USA), Bcl-xl (polyclonal, 1 : 300; Santa Cruz, USA), or actin (polyclonal, 1 : 200; Roche, Germany) . (a-d) Western blot analysis was performed on CNE2 and CNE2-MAD2-C3 cells treated with vincristine (3 ng/ml) (a-c) or taxol (1.5 ng/ml) (d) at indicated time points in the presence (+P) or absence (ÀP) of ponasterone A. Note that increased Raf, MEK1/2 and Bcl-2 phosphorylation is found in the cells expressing exogenous MAD2 protein (+P) after exposure to vincristine. There is no increase in Raf/Bcl-2 phosphorylation after exposure to taxol. E: Effect of MEK1/2 inhibitor PD098059 on MAD2-induced sensitization to vincristine in CNE2-MAD2-C3 cells. (1) Cells were treated with vincristine (3 ng/ml) and PD098059 for 24 h in the presence (+P) or absence (ÀP) of ponasterone A. (2) Effect of PD098059 on colony-forming ability after continuous exposure to vincristine. PD098059 was added together with vincristine for 12 days in the presence or absence of ponasterone A. Two wells were used for each concentration and each experiment was repeated at least three times. Results represent the means and standard error of the means next studied the effect of taxol on Raf and Bcl-2 expression in CNE2 cells. As shown in Figure 4d , we did not observe any changes in the levels of phosphorylated Raf or Bcl-2 proteins after exposure to taxol (1.5 ng/ml), regardless of MAD2 status. These results indicate that taxol-induced cell death in CNE2 cells may be independent of Raf/Bcl-2 phosphorylation as previously reported in human ovarian cancer cells (Wang TH et al., 1999) .
To exclude the possibility that ponasterone A treatment alone might affect the phosphorylation of Raf, MEKl/2 and Bcl-2, we also studied the parental CNE2 cells cultured in identical conditions to CNE2-MAD2-C3 as a negative control. As shown in Figure 4 (CNE2), the expression levels of all three proteins were similar in CNE2 cells (7P) compared to the CNE2-MAD2-C3 cultured in the absence of ponasterone A, suggesting that ponasterone A treatment had no effect on the phosphorylation of these proteins.
To further support the hypothesis that Raf/Bcl-2 phosphorylation is essential for MAD2-induced sensitization to vincristine, we treated CNE2-MAD2-C3 cells with a MEK1/2 inhibitor, PD098059, which has been shown to inactivate specifically MEK1/2 signaling by reducing its phosphorylation (Huang et al., 1999) . We found that after exposure to PD098059 (50 and 75 mm) for 24 h, the vincristine-treated CNE2-MAD2-C3 cells showed decreased MEK1/2 phosphorylation in the presence of ponasterone A, which was accompanied by a dose-dependent decrease in Bcl-2 phosphorylation (Figure 4e1, upper band) . In addition, the colony-forming ability of these cells was enhanced by PD098059 treatment (75 mm) against vincristine (Figure 4e2, +P+PD098059 ), compared to the untreated cells (+P). However, we did not observe significant changes in either phosphorylation of MEKl/2 or the colony-forming ability in these cells cultured in the absence of ponasterone A (Figure 4e2 , ÀP+PD098059; ÀP). These results suggest that MAD2 expression is associated with Raf/MAPK activation and that Bcl-2 phosphorylation is essential for MAD2-induced sensitization to vincristine. The fact that Bcl-2 phosphorylation occurred subsequently to the activation of Raf/MAPK indicates that activation of Raf/MAPK may be responsible for the inactivation of Bcl-2, as previously suggested (Blagosklonny et al., 1997) .
Activation of Raf kinase through phosphorylation, mainly at serine residues, has been demonstrated during mitosis (Laird et al., 1995; Lovric and Moelling, 1996) . Recently, it has been suggested that Raf activation may be responsible for the cytotoxicity of certain microtubule-2 disrupting agents including vincristine, since activated Raf kinase is essential for phosphorylation of Bcl-2 leading to apoptosis (Blagosklonny et al., 1997; Huang et al., 1999; Fan et al., 2000) . In the present study, we found increased phosphorylation of Raf and MEK1/2 in the vincristinetreated MAD2-overexpressing CNE2 cells (Figure 4b ).
One possibility is that MAD2 acts as an essential component of a signaling pathway that leads to Raf and MAPK activation. Vincristine and other microtubuledisrupting agents may target the mitotic checkpoint and activate MAD2, thereby inducing Raf and MAPK activation. In addition, in the present study, the activation of the MAPK pathway was also accompanied by the increased phosphorylated Bcl-2 in the MAD2-overexpressing cells compared to the cells with insufficient MAD2 (Figure 4c ). Inactivation of MEK1/ 2 by inhibiting its phosphorylation resulted in the decreased Bcl-2 phosphorylation and increased colonyforming ability in MAD2-expressing cells (Figure 4e ). These results implicate that the MAD2-induced hypersensitivity to vincristine may be through phosphorylation of Bcl-2 as a result of Raf/MAPK activation in CNE2 cells.
Another interesting observation in the present study is that exogenous MAD2 expression did not significantly affect the sensitivity of CNE2 cells to taxol. It is understood that taxol and vincristine are two contrasting examples of microtubule-interfering agents. Vincristine binds to tubulin subunits and inhibits microtubule polymerization, thus disrupting spindle dynamics and leading to mitotic block. In sharp contrast, taxol enhances tubulin polymerization by inhibiting microtubule disassembly, which then prevents the breakdown of microtubules that is also required for progression of the cell division cycle. The function of MAD2, however, is to sense microtubule attachment and once an unattached kinetochore is detected, MAD2 generates the 'wait' signal to stop progression to mitosis (Zhang and Lees, 2001 ). In the cells treated with vincristine, unattached kinetochores are present, while in the cells treated with taxol, most kinetochores are attached to the microtubules. Therefore, it is not surprising that MAD2 governs the cellular sensitivity to vincristine but not to taxol. Presumably, vincristine and taxol may target different steps of the same mitotic checkpoint. In addition, the fact that we did not find increased phosphorylation of Raf/Bcl-2 in CNE2-MAD2-C3 cells treated with taxol (Figure 4d ) further support this hypothesis. Nevertheless, the functions of MAD2 are still largely unknown, neither is it clear exactly how mammalian cells escape mitotic arrest induced by microtubule disruption. Thus, further studies are required to elucidate the physiological roles of MAD2 and the integration of its checkpoint function with the programs of cellular proliferation and apoptosis.
In summary, in this study we report for the first time that exogenous MAD2 expression resulted in an increased sensitivity to a microtubule-disrupting anticancer agent, vincristine, in NPC cells. Inactivation of Bcl-2 by phosphorylation, possibly through the activation of the Raf/MAPK pathway, may be responsible for the sensitization effect in these cells. Our results implicate a novel mechanistic link between MAD2 and cellular sensitivity to certain microtubule-interrupting agents.
